AVPR2 and autosomal dominant polycystic kidney disease: We therefore investigated in subjects with ADPKD whether fasting plasma concentration of endogenous SST is associated with 1) urinary cAMP excretion 2) disease severity and 3) disease progression, and 4) whether plasma SST concentration changes on treatment with the vasopressin V2 receptor antagonist tolvaptan or the SST analogue lanreotide.